Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03382158 · ClinicalTrials.gov registry record

International PPB/DICER1 Registry

A clinical trial of Wilms Tumor and Pineoblastoma, sponsored by Children's Hospitals and Clinics of Minnesota.

Recruiting
Registry status
3,400
Enrollment target
1
Study location

NCT03382158: Recruiting study of Wilms Tumor and Pineoblastoma, sponsored by Children's Hospitals and Clinics of Minnesota.

NCT03382158 is a study of Wilms Tumor and Pineoblastoma that is actively recruiting participants, run by Children's Hospitals and Clinics of Minnesota. The registered enrollment target is 3,400 participants, above the 50-participant average among 14 other Wilms Tumor trials with a reported enrollment target (6700% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03382158, a study of Wilms Tumor and Pineoblastoma, is actively recruiting participants, sponsored by Children's Hospitals and Clinics of Minnesota.

RECRUITING
Registry status
3,400 participants
Enrollment target
1
Study location

Study Summary

Pleuropulmonary blastoma (PPB) is a rare malignant neoplasm of the lung presenting in early childhood. Type I PPB is a purely cystic lesion, Type II is a partially cystic, partially solid tumor, Type III is a completely solid tumor. Treatment of children with PPB is at the discretion of the treating institution. This study builds off of the 2009 study and will also seek to enroll individuals with DICER1-associated conditions, some of whom may present only with the DICER1 gene mutation, which will help the Registry understand how these tumors and conditions develop, their clinical course and the most effective treatments.

Primary Outcome

The primary endpoint for statistical analysis will be time from start treatment to an event, defined as the occurrence of progression or recurrence of PPB, occurrence of a second malignant neoplasm, or death from any cause that is at least possibly related to the original disease or treatment.

Study Locations (1)

Minnesota

  • Children's Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 3,400 participants
Start Date 2016-12-06
Est. Completion 2035-12-06

What NCT03382158 shows while recruiting

NCT03382158 is an observational study that tracks outcomes without assigning an intervention. Its 3,400 participants enrollment target places it among the larger protocols in the corpus, above the 50-participant average among 14 other Wilms Tumor trials with a reported enrollment target (6700% higher).

The record links to 10 conditions, with Wilms Tumor appearing as the primary indexed condition, and to 0 interventions.

NCT03382158 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT03382158 about?

NCT03382158 is a clinical study titled "International PPB/DICER1 Registry". Pleuropulmonary blastoma (PPB) is a rare malignant neoplasm of the lung presenting in early childhood. Type I PPB is a purely cystic lesion, Type II is a partially cystic, partially solid tumor, Type III is a completely solid tumor. Treatment of children with PPB is at the discretion of the treating...

What is the current status of trial NCT03382158?

This trial is currently recruiting. The enrollment target is 3,400 participants. The study started on 2016-12-06. Estimated completion is 2035-12-06.

What conditions does trial NCT03382158 study?

This clinical trial studies the following conditions: Wilms Tumor, Pineoblastoma, Pleuropulmonary Blastoma, DICER1 Syndrome, Cystic Nephroma.

Who is sponsoring clinical trial NCT03382158?

This trial is sponsored by Children's Hospitals and Clinics of Minnesota, which has 31 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03382158 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Wilms Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03382158's enrollment target sits among peer trials

3,400 1st of 14 higher than 14 of 14 other Wilms Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Wilms Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03474029 · 3,400 participants · Phase 2

    Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI

  • NCT07142954 · 3,400 participants · Phase 3

    Epidemiology and Biomarker Study in Alzheimer's Disease

  • NCT06880055 · 3,375 participants

    Shield Post-Approval Study Protocol

  • NCT03674307 · 3,306 participants · NA

    Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03382158, the US trial registry maintained by the National Library of Medicine. NCT03382158 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.